● Recruiting

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

Condition: Solid Tumors · Refractory Cancer · Sponsor: Chiome Bioscience Inc.

PhasePhase 1

Planned participants70

Who can joinAll sexes, 20 Years to no upper limit

Healthy volunteersNo

About this study

This is a First in Human muticenter, non-randomized, open-label Phase I dose-escalation study of CBA-1535. The study will have 2 parts (Part 1 and Part 2). Part 1 is the dose-escalation cohorts of CBA-1535 single agent theapy. Part 2 is the dose-escalation cohorts of CBA-1535 in combination with Pembrlizumab. This study will evaluate the safety, tolerability, PK, biomarker profiles and preliminary efficacy of CBA-1535.

This description comes directly from the study's public registry record.

Talk to the study team

Chiome Bioscience Inc. · +81-3-6383-3561 · ir@chiome.co.jp

Always discuss trial participation with your own doctor first.

Locations (2)

Shizuoka Cancer Center	Nagaizumicho, Shizuoka, Japan	Recruiting
National Cancer Center Hospital	Chuo-Ku, Tokyo, Japan	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07016997